MEIP vs. ORGS, LUMO, TCRT, SYBX, BNTC, BIVI, CPIX, NRBO, KALA, and GDTC
Should you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Orgenesis (ORGS), Lumos Pharma (LUMO), Alaunos Therapeutics (TCRT), Synlogic (SYBX), Benitec Biopharma (BNTC), BioVie (BIVI), Cumberland Pharmaceuticals (CPIX), NeuroBo Pharmaceuticals (NRBO), KALA BIO (KALA), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical preparations" industry.
MEI Pharma (NASDAQ:MEIP) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
In the previous week, MEI Pharma had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for MEI Pharma and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.43 beat MEI Pharma's score of 0.92 indicating that Orgenesis is being referred to more favorably in the news media.
MEI Pharma received 375 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 60.74% of users gave MEI Pharma an outperform vote.
MEI Pharma has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks.
MEI Pharma has a net margin of 39.06% compared to Orgenesis' net margin of -1,010.50%. MEI Pharma's return on equity of 48.32% beat Orgenesis' return on equity.
MEI Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
52.4% of MEI Pharma shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 3.9% of MEI Pharma shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
MEI Pharma currently has a consensus price target of $7.00, indicating a potential upside of 122.22%. Given MEI Pharma's higher probable upside, equities research analysts clearly believe MEI Pharma is more favorable than Orgenesis.
Summary
MEI Pharma beats Orgenesis on 11 of the 16 factors compared between the two stocks.
Get MEI Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MEI Pharma Competitors List
Related Companies and Tools
